COMP

Across TCGA pan-cancer cohorts, COMP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated COMP data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher COMP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated COMP expression acts as an unfavorable survival marker.

LIHC, DLBC, and UCEC are the cancer types where COMP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.320	0.780	<.001	24	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	II,III,IV	0.232	0.680	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

COMP–LIHC (OS)

Open the LIHC breakdown →